Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies.

William J SandbornJingjing ChenKrisztina KisfalviEdward V LoftusGeert D'HaensNinfa CandelaKaren LaschDouglas C WolfSharif M UddinSilvio Danese

Published in: Crohn's & colitis 360 (2023)

Clinical real-world scenarios with vedolizumab SC were reviewed using VISIBLE studies data. Vedolizumab SC provides an additional dosing option for patients with UC and CD.

Keyphrases

ulcerative colitis
climate change
case control
patients with inflammatory bowel disease
electronic health record
big data
machine learning
nk cells